Drug Trial Radar · NCT06509906
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Oct 8, 2024
Primary completion
Dec 2, 2025
Study completion Dec 2, 2025
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jul 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens. As such the combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) and Bevacizumab will be evaluated in participants with colorectal cancer, to establish the M9466 maximum tolerated dose if observed and the recommended dose for expansion. Study Duration: After a Screening period of up to 28 days, enrolled participants will remain in the study until they have completed all the study visits or until they withdraw consent, are lost to follow-up, or die. Visit Frequency: The participants will come for a Screening Visit and 1 to 2 visits per treatment cycle. After end of study intervention period, the participants will come for an End of Treatment Visit and a Safety Follow-up Visit.
Conditions
- Advanced Solid Tumor
Interventions
M9466Drug
M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
IrinotecanDrug
Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
Folinic acidDrug
Folinic acid will be administered intravenously q2w as per standard of care.
Fluorouracil (5-FU)Drug
Fluorouracil will be administered intravenously as per standard of care.
BevacizumabDrug
Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
Granulocyte colony stimulating factor (G-CSF)Drug
G-CSF will be administered subcutaneously at every cycle of study intervention as per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEsTime frame: Time from signing Informed Consent Form (ICF) up to 30 days after end of study intervention (approximately assessed up to 18.7 months)
- Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Day 1 up to Day 28 of the first two Cycles (each cycle is of 14 days)
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at Health One
Denver, Colorado
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
Pennington, New Jersey
Vanderbilt University - 150912667
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Cancer Research SA
Elizabeth Vale, Australia
St George Private Hospital
Kogarah, Australia
Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC
Parkville, Australia
National Cancer Center Hospital
Chūōku, Japan
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
NEXT Barcelona - NEXT Barcelona
Barcelona, Spain
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.